Abstract: Humanized mice are a powerful tool to study HIV in vivo. The recently generated mouse strains MITRG and MISTRG, which differ in human SIRP expression, support an improved human myeloid lineage development from human hematopoietic stem and progenitor cells. The rationale of the study was the characterization of the two mouse strains during an HIV infection with CCR5-and CXCR4-tropic viruses. Upon HIV infection, we observed HIV dissemination and sustained viral load over 20 wk in peripheral blood in both reconstituted mouse strains. However, HIV RNA levels were significantly lower in MITRG mice compared with MISTRG mice during the first 8 wk postinfection. HIV-infected MISTRG mice showed lymphocyte activation and changes in lymphocyte subsets in blood and spleen, recapitulating hallmarks of HIV infection in humans. Depletion of murine tissue-resident macrophages in MITRG mice led to significantly elevated viral loads, and lymphocyte levels were similar to those in HIV-infected MISTRG mice. Depletion of CD8+ T cells in MISTRG mice before HIV infection resulted in substantially decreased CD4+ T cell levels, indicating functionality of human CD8+ T cells; depletion of CD4+CD8+ thymocytes may have contributed, in part, to the latter finding. In summary, MITRG and MISTRG mice represent novel HIV mouse models, despite differential HIV dynamics. 
INTRODUCTION
Humanized mice (hu mice) have become a valuable tool for studying human hematopoiesis in health and disease (1) . In the last two decades, different knockouts (i.e., Rag1/2 2/2 and Pkrdc 2/2 ) have made mice more receptive to accepting human xenografts. NOD-SCIDgc 2/2 (NSG), NOD-SCID truncated gc (NOG), NOD
Rag1
2/2 gc 2/2 (NRG), and Rag2 2/2 gc 2/2 mice are the most commonly used mouse strains for humanization (2) (3) (4) . In the mid2000s, transplantation of umbilical cord blood-derived CD34 + hematopoietic stem and progenitor cells (HSPCs) into irradiated newborn pups by intrahepatic (4) or i.v. injection (5) was tested and resulted in higher levels of multilineage hematopoiesis than the transplantation of human CD34 + cells into adult mice (6) .
Notably, NRG and NSG mice support better engraftment than Rag2 2/2 gc 2/2 mice (6, 7). The rather modest engraftment in
Rag2
2/2 gc 2/2 mice is explained by the inadequate "don't-eat-me"
signal that human cells transmit to murine macrophages. This signal relies on the proper interaction of the ubiquitously expressed human CD47 and SIRPa on myeloid-monocytic cells. Indeed, mice on a NOD background have a SIRPa allele that efficiently recognizes human CD47 and, thus, provides the murine macrophages with the corresponding inhibitory signal (8) .
To improve xenograft acceptance in hu mice with a missing CD47-SIRPa interaction, transgenic expression of human SIRPa (9) , murine CD47 expression on human cells by lentiviralmediated gene transfer (10) , or more recently, knockout of murine CD47 (11) have been reported. In fact, the SIRPa-CD47 axis leads to decreased engraftment of human acute leukemia stem cells in hu mice on the NOD background (12) .
The supply of human cytokines is critical for engraftment and subsequent multilineage hematopoiesis in hu mice. Several human and mouse cytokines were reported to support immune cell homeostasis in both species (13, 14) , but human cells remain poorly reactive to some murine cytokines as a result of their low homology (15) . Historically, the injection of various cytokines (e.g., IL-3, SCF, GM-CSF) was used to boost human cell engraftment (16) (17) (18) . In addition, injection of cytokines was reported to enhance the engraftment of distinct populations, such as NK cells, T cells, and plasmacytoid dendritic cells (19) (20) (21) (22) . To overcome the need for human cytokine administration, which, in general, does not provide physiological levels, human cytokine knock-in strains of immunodeficient mice were engineered. Thus, various knock-in mice of the Rag2 2/2 gc 2/2 strain were created, bearing human TPO (14) , GM-CSF/IL-3 (23) , and M-CSF (14) . Two novel humanized mouse models were recently reported (24) that combine the knock-in transgenes of a number of human cytokines (i.e., human M-CSF, IL-3, TPO, and GM-CSF) in Rag2 2/2 gc 2/2 mice on a mixed Balb/c 3 129 background. The mouse strain was named MITRG. The second one, MISTRG, also expresses the human SIRPa through a bacterial artificial chromosome (9) . MITRG and MISTRG mice support better human myeloid cell engraftment than the current gold standard NSG mice and closely mirror the human hematopoietic profile (24) . In addition to the efficient engraftment of cord blood-derived CD34 + , MISTRG mice show superior engraftment of mobilized peripheral blood CD34 + cells and myeloid lineage development in comparison with other mouse strains (25) .
HIV is a human-specific virus. Hu mice fill the long-needed gap for conducting in vivo HIV research. Most HIV studies in hu mice were done with humanized Rag2 2/2 gc 2/2 (26, 27) , NOG (28), or NSG (29) mice. Hu mice have been used to study HIV pathogenesis (30) (31) (32) and to explore novel therapeutic modalities (33, 34) , including gene engineering of an HIV-resistant immune system (35, 36) . Naturally, HIV research benefits from the ongoing efforts to improve humanization in mice. Thus, the aim of this study was to explore the value of MITRG and MISTRG mice for studying HIV. The innate immune system plays an important role during HIV infection. With the development of MITRG and MISTRG mice, we now have the opportunity to study these interactions in a small animal model with a relatively prominent myeloid system. Specifically, we aimed to characterize some aspects of acute and asymptomatic HIV infection, to monitor the differential dynamics of diverse cell types, and to explore whether the absence of human SIRPa would influence viral replication in humanized MITRG mice.
MATERIALS AND METHODS

Generation of hu mice
Humanized MISTRG and MITRG mice were generated essentially as described (24) . In brief, newborn MISTRG and MITRG mice were injected intrahepatically with 2.0 3 10 5 CD34 + HSPCs derived from umbilical cord blood within the first 3 d after birth.
MISTRG and MITRG mice were bred and maintained in individual ventilated cages and were fed autoclaved food and water. Mice were monitored weekly for symptoms or signs of adverse events, according to a standard score sheet. Engraftment was checked in peripheral blood at 9-10 wk of age, and animals with an engraftment . 5% human CD45 + (hCD45 + ) cells in peripheral blood were used for experiments.
Virus production and infection Viral stocks were obtained by polyethylenimine-mediated transfection (Polysciences) of HEK293T cells (American Type Culture Collection, Manassas, VA) with p-YU-2 or p-NL4-3 (provided through the National Institutes of Health AIDS Research and Reference Reagent Program). At 48 h after transfection, virus was harvested, filtered (0.22 mm), and frozen at 280°C until use. Viral titers were determined as described (37) . Briefly, 50% tissue culture infectious dose (TCID 50 ) was determined by infecting human CD8 + T cell-depleted PBMCs from three healthy donors that were stimulated by the addition of IL-2, PHA, and anti-CD3 beads (Dynal 11131D; Life Technologies). Mice were infected i.p. with HIV YU-2 or NL4-3 at 200,000 TCID 50 per mouse. HIV RNA plasma levels were measured by RT-PCR (AmpliPrep/COBAS TaqMan HIV-1 Test; Roche) at different time points postinfection (p.i.).
CD34
+ cell isolation from umbilical cord blood HSPCs were isolated from human cord blood with anti-CD34 immunomagnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany) with a yield of 0.5 to 4 310 6 HSPCs (purity $ 90%). HSPCs and "nontargeted" fractions were stored frozen in liquid nitrogen until use.
Immunophenotypic analysis of blood and organ cells
The following human cell surface markers were used for immunophenotyping of peripheral blood and splenocytes: CD45, CD33, CD3, CD16, CD14, CD19, NKp46, CD4, CD8, HLA-DR, CD38, CD11b, CD68, and CD163 and murine CD45, CD11b, Ly6C, F4/80, and CD68 (all Abs were purchased from BioLegend, BD Biosciences, and Beckman Coulter). Washing and reagent dilutions were done with PBS or with FACS buffer (PBS containing 2% FBS and 0.05% sodium azide). Before acquisition, cells were fixed with 1% paraformaldehyde (Sigma). All acquisitions were performed on a Cyan ADP (Beckman Coulter) flow cytometer.
Data were analyzed with FlowJo 10 software (TreeStar, Ashland, OR). Cellular debris and dead cells were excluded by their lightscattering characteristics or with live/dead fixable stain (Zombie NIR; BioLegend).
Mononuclear phagocytic cell and CD8
+ T cell depletion Mice were treated i.p. with clodronate liposomes (CLDs; http:// www.clodronateliposomes.org; 1 mg/20 g body weight) at 9 wk of age, followed by HIV YU-2 infection 48 h later. The maintenance dose was 0.5 mg/20 g body weight once weekly during the course of the experiment. CD8 + T cell depletion was accomplished as described (38) . Briefly, 50 mg of anti-CD8 + T cell Ab OKT8 (Bio X Cell) was administered i.p. on three consecutive days, followed by HIV YU-2 infection. CD8 + T cell depletion was maintained by repeating the procedure every 2 wk, and the depletion was monitored in the peripheral blood.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 6 (GraphPad). Data were subjected to an unpaired Mann-Whitney U test, Kruskal-Wallis test, or Spearman correlation, as indicated in the figure legends. The obtained p values were considered significant at p , 0.05.
Study approval
All animal experiments as well as procurement of human cord blood were approved by ethical committees of the University of Zurich and the Federal Veterinary Department. All animal experimentation was approved by the cantonal veterinary office Zurich (#93/2014). The experiments were conducted according to local guidelines and the Swiss animal protection law. Human cord blood was collected with informed written consent of the parents.
RESULTS
Engraftment levels of nonirradiated MISTRG and MITRG mice
Hu MISTRG and MITRG mice with an engraftment . 60%, as assessed by peripheral blood staining for the pan-human leukocyte marker CD45, are at risk for developing anemia over a short time period as the result of inefficient formation of human RBCs and concomitant phagocytosis of mouse RBCs by human macrophages (24) . Omitting irradiation prior to transplantation of CD34 + human HSPCs resulted in reduced engraftment, but it decreased the incidence of anemia. Because we opted for an extended period of experimentation, we transplanted without preconditioning and obtained blood engraftment of hCD45 + cells of 31.67 6 2.94% and 16.53 6 1.94% (mean 6 SEM, p # 0.001) in MISTRG and MITRG mice, respectively, at 9 wk of age (Fig. 1A) .
We also observed differences in human lymphoid and myeloid cell populations in the blood of MISTRG and MITRG mice (Fig.  1B) Fig. 2A) . Intriguingly, MISTRG mice had a viral peak at 8 wk p.i., and MITRG mice showed a progressive increase in HIV copy number toward the levels observed in MISTRG mice at 16 wk p.i. We noticed substantial differences in the percentages of CD3 + T cells between the groups (Fig. 2B) . Initially, in MISTRG mice, 18.42 6 3.17% of total hCD45 + cells were CD3 + T cells, and their frequency progressively increased to 84.10 6 8.65% in the peripheral blood during the course of infection (Fig. 2B ). In contrast, MITRG mice had low levels (2.74 6 0.55%) at baseline, increasing up to 37.60 6 9.28% at 20 wk p.i., which remained significantly below the CD3 + T cell frequency in MISTRG mice. Within the CD3 + T cell population, CD4 + T cells in MISTRG mice expanded up to week 8 p.i., when HIV replication peaked, and then declined (Supplemental Fig. 1 ). In contrast, levels of CD8 + T cells constantly increased (Supplemental Fig. 1 ).
HIV infection promotes immune activation of T cells. In MISTRG mice, we observed a positive correlation between the viral load in the plasma and CD38 + HLA-DR + CD4 + T cells ( Fig. 2C ) and CD8 + T cells (Fig. 2D) in the blood at week 4 p.i.. These analyses were not conclusive in MITRG mice because of the low CD3 + T cell numbers. At sacrifice at 12 or 20 wk p.i., we observed similar distributions of cell populations in the spleen (Fig. 2E ) as in the blood (Fig. 1B) of uninfected MISTRG and MITRG mice. In infected animals, a substantial increase in the percentage of splenic CD3 + T cells compared with uninfected ones was observed in both strains, particularly in MISTRG mice (8.02 6 5.28% versus 58.00 6 12.54% CD3 + T cells of hCD45 + cells, p = 0.033). We also noted increases in the activation of CD8 + and CD4 + splenocytes in MISTRG mice, as well as in MITRG mice, as quantified by the expression of CD38 and HLA-DR (Fig. 2F, 2G ).
Changes in differentiation subsets of CD4
+ and CD8 + T cells in MISTRG mice during acute and chronic HIV infection HIV infection in humans is divided into three stages: acute HIV infection (the first 12 wk after transmission), chronic HIV infection, and the late stage, known as AIDS. Similarly, in our experiments, we defined acute infection as the first 12 wk p.i. (T CM ) showed a tendency to decrease in infected MISTRG mice during acute infection compared with uninfected mice (Fig. 3B) . During the chronic phase, we observed a shift from T EMRA to T EM in the CD4 + T cell compartment, with a concomitant decrease in T N in comparison with uninfected MISTRG mice.
During the acute phase of infection, T EM and T CM remained stable among CD8 + T cells, but there was a significant increase in T EMRA and concomitantly lower frequencies of T N (Fig. 3B) . Similar to the CD4 + T cell compartment, we observed a trend for a shift from T EMRA to T EM among CD8 + T cells (p = 0.1175) compared with uninfected animals.
Notably, the expression of PD-1 is upregulated on terminally differentiated T cells after their activation during acute viral infections (40) . Thus, we assessed the median fluorescent intensity of PD-1 in CD4 + splenocytes, which revealed a differential expression (Fig. 3C) . The expression of PD-1 was significantly elevated in CD4 + T EMRA ; however, it was downregulated during the acute phase of infection in all other subsets. In the chronic phase, PD-1 levels on T EMRA remained comparable to those during acute infection, whereas a substantial increase was observed in T CM (p = 0.0043) and T EM (p = 0.026).
In CD8 + splenocyte subsets, PD-1 expression was increased on T N , T CM , and T EMRA (Fig. 3D) . A significant decrease in PD-1 was detected on T EM during acute infection. In the chronic phase, only PD-1 levels on T EM were significantly increased (p = 0.0043) (Fig. 3D) .
Overall, this dynamic of cellular changes indicated an ongoing immune response upon HIV infection. However, hCD45 + splenocytes isolated from animals during acute infection and 
Sustained HIV NL4-3 infection in MISTRG and MITRG mice
We also infected MISTRG and MITRG mice with the CXCR4-tropic strain, NL4-3. Similar to infection with the CCR5-tropic strain, YU-2, HIV replication was higher in MISTRG mice than in MITRG mice (Fig. 4A) The level of CD3 + T cells in the peripheral blood continuously increased until 8 wk p.i. in MISTRG mice infected with NL4-3, despite vigorous HIV replication (Fig. 4B) ; however, this expansion was lower than in mice infected with YU-2 (Fig. 2B) . We also detected increasing levels of CD3 + T cells in MITRG mice at 12 wk p.i with NL4-3, which was at an earlier time point than in In both infection models, the CD4 + T cell percentage was lower in infected mice than in the uninfected control groups, displaying the highly cytopathic nature of CXCR4-tropic strains (41) (Supplemental Fig. 1 ).
In accordance with data generated during CCR5-tropic infection, we detected CD38 + HLA-DR + CD4 + (Fig. 4C ) and CD8 + (Fig. 4D ) T cells at 4 wk p.i., the percentages of which correlated with HIV RNA copy numbers in the plasma. Similar to YU-2 infection, we found more CD3 + T cells in the spleens of NL4-3-infected MISTRG mice than in uninfected MISTRG mice (Fig. 4E) . In contrast, we did not observe any increase in T cells in MITRG mice. Cellular subset analysis revealed more activated CD38 + HLA-DR + CD8 + splenocytes in HIV-infected mice than in uninfected ones (Fig. 4F) .
No effect of CD8 + T cell depletion on HIV viral load in MISTRG mice
We observed a tendency for decreasing viral loads after 8 wk p.i. in MISTRG mice infected with the CCR5-or CXCR4-tropic strain (Figs. 2A, 4A ). We hypothesized that CD8 + T cells were responsible for this observation. We depleted CD8 + T cells by administering the anti-human mAb OKT8 to MISTRG mice before HIV infection. To maintain depletion, we administered OKT8 every 2 wk until the mice were sacrificed 5 wk later. The depletion was efficient because we did not detect any CD8 + T cells in the peripheral blood (Fig. 5A) . We did not detect differences in viral load with or without CD8 + T cells in MISTRG mice (Fig. 5B) . Notably, we observed a trend of a less steep increase in viral load in CD8 + T cell-depleted animals at 2 wk p.i.; this could be due to an OKT8-mediated depletion of CD4 + CD8
+ thymocytes and an overall decrease in CD3 + T cell levels (Supplemental Fig. 2 ), leading to a loss of HIV target cells or the release of chemokines/ cytokines by CD8 + T cells. At the end of the experiment, a significant decrease in CD4 + T cell percentage was detected in the spleens and blood (data not shown) of CD8 + T cell-depleted and infected MISTRG mice compared with uninfected CD8 + T celldepleted animals (Fig. 5C ). This probably reflects the combined CD4 + T cell depletion resulting from the reduction of CD4 + CD8 + thymocytes by the OKT8 Ab and the destruction of CD4 + T cells by HIV.
We administered OKT8 to MITRG mice as well. In contrast to HIV-infected and CD8 + T cell-depleted MISTRG mice, we observed a tendency toward a decreased viral load in OKT8-treated MITRG mice (Supplemental Fig. 3 ). Similar to OKT8-treated MISTRG mice, this might be linked to the diminished CD3 + T cell levels (Supplemental Fig. 3 ). In addition, MITRG mice receiving OKT8 showed decreased levels of CD4 + T cells during infection compared with uninfected controls, suggesting destruction. In addition, we investigated the distribution of CD4 + splenocyte subsets as depicted (Fig. 3A) . CD8 + T cell-depleted uninfected mice showed no significant differences (Fig. 5D ) from untreated uninfected controls (Fig. 3B) . Upon YU-2 infection in depleted animals, a significant increase in the T CM compartment was detected, with concomitant decreases in T N , T EMRA , and T EM (Fig. 5D ) compared with uninfected OKT8-treated MISTRG mice.
HIV replication profile in MISTRG mice restored in MITRG mice by phagocytic cell depletion MITRG and MISTRG are identical mouse strains that differ only in the expression of human SIRPa. We hypothesized that the differences in viral load and percentage of CD3 + T cells seen between HIV-infected MITRG and MISTRG mice are caused by expression of human SIRPa on murine cells. To simulate a situation free of phagocytic cells in MITRG mice, and therefore recapitulate some of the features of MISTRG mice, we administered CLDs to MITRG mice. Briefly, MITRG mice were treated with CLDs, followed by YU-2 infection 48 h later (Fig. 6A) . The depletion was maintained by repeated weekly injections of CLDs for 3 wk. The CLD protocol used was very efficient, because we did not find any murine CD68 + F4/80 + tissue-resident macrophages in the spleen at euthanasia. The CLD treatment administered for 3 wk led to a higher blood engraftment level than the mock treatment (PBS: 12.67 6 1.82%, CLD: 30.65 6 4.86% hCD45 + [mean 6 SEM], p = 0.0221) (Fig. 6B ). The HIV load was three-log higher in CLD-treated mice than in mock-treated mice (Fig. 6C) . The eventual viral load of the CLD group was even greater than that in HIV-infected MISTRG mice ( Fig. 2A) . Remarkably, the depletion of phagocytic cells in MISTRG mice promoted further HIV replication (Supplemental Fig. 4) .
CLD treatment also resulted in some remarkable cellular changes in the blood: we observed an increase in NKp46 + cells in HIV-infected MITRG mice (Fig. 6D) . Similar to previously observed increases in activated CD4 + and CD8 + T cells in YU-2-infected MISTRG mice, we detected elevated levels in CLD-treated MITRG mice (Fig. 6E) . However, we did not detect activated T cells in CLDtreated MISTRG mice (Supplemental Fig. 4) .
Human cell engraftment was substantially elevated, up to ;40% of hCD45 + cells, in spleens of CLD-treated MITRG mice (Fig. 6F ). Splenic cell distributions resembled those in the peripheral blood of MISTRG mice at 9 wk of age (Fig. 1B) . Significantly, more CD3 + splenocytes were observed in uninfected and infected CLD-treated MITRG mice than in PBS control mice. Furthermore, we found a significant increase in human CD68 + CD163
2 and CD68 + CD163 + splenic macrophages in CLD-treated mice, irrespective of HIV infection (PBS p = 0.008) (Fig. 6F) . Moreover, HIV infection alone appeared to induce expansion of CD68 + CD163 + macrophages. Taken together, the depletion of macrophages in MITRG mice reproduced, in essence, the data observed in MISTRG mice and supports our hypothesis that the expression of human SIRPa on murine macrophages is at the origin of the differences observed between HIV-infected humanized MITRG and MISTRG mice.
DISCUSSION
In this study, our main findings were that, even without preconditioning, we obtained efficient engraftment levels in MI(S) TRG mice; reconstituted MITRG and MISTRG mice are susceptible to HIV infection with distinct coreceptor selectivity, and the infection is sustained over 20 wk; MITRG mice show a different pattern of HIV infection compared with MISTRG mice, in terms of lower HIV replication and T cell levels; the HIV-replication profile in MISTRG mice is restored in MITRG mice by depleting phagocytic cells, resulting in increased viral loads and higher engraftment levels; and CD8 + T cell depletion in HIV-infected MISTRG mice induces massive CD4 + T cell depletion but has no effect on HIV replication rate. Clodronate treatment removes the negative regulation of xenogenic murine macrophages on human hematopoiesis and allows a faster HIV pathogenesis; thus, the similar HIV-replication pattern in HIV-infected MISTRG mice and macrophage-depleted MITRG mice points to a particular role for SIRPa in these HIV models. Overall, both models are suitable for the study of the interplay between the immune system and HIV. Irradiation of MISTRG mice promotes liberation of space in the bone marrow niche for injected human CD34 + cells, and high levels of multilineage human hematopoiesis are supported by the knock-in of human cytokines. This, in turn, may result in severe anemia and limited experimentation and lifespan (24) . Similar observations were made in MIS (KI) TRG mice (42), a novel mouse model similar to MISTRG mice that expresses the human SIRPa from the corresponding mouse locus instead of a bacterial artificial chromosome transgene. Thus, we transplanted newborn mice without any preconditioning with cord blood HSPCs and obtained slightly lower engraftment levels at 9 wk of age than in irradiated animals transplanted with fetal liver-derived HSPCs (24) . However, we observed that human peripheral cells waned at ;36 wk of age. Furthermore, MITRG/MISTRG mice also support engraftment with mobilized peripheral blood CD34 + cells from adults (43) . Thus, MITRG/MISTRG mice support engraftment of any kind of CD34 + cells, with more prominent engraftment if irradiated prior to transplantation. Reconstituted MISTRG and MITRG mice showed sustained and robust HIV replication of the CCR5-tropic strain, YU-2, and the CXCR4-tropic strain, NL4-3, over 20 wk (44) . This HIV replication was paralleled by an expansion of the CD3 + T cell population in HIV-infected mice; indeed, in the YU-2-infected MISTRG mice, we even observed an initial expansion of CD4 + T cells, followed by a decline, reminiscent of HIV infection in humans. However, we are challenged by the paradoxical waning of human CD3 + T cells over time in uninfected mice. Thus, HIV appears to be a transient stimulus for the human graft. The constellation observed might be due to a less efficient engraftment in mice without preconditioning compared with mice with preconditioning. Notably, reconstitution without preconditioning results in limited lifetime of the human graft (45) . 
Downloaded from
We found an increase in CD4 + and CD8 + T EMRA 5 wk p.i., pointing to an immune response against HIV concomitant with a decrease in CD4 + T EM , an HIV target in early infection (46) .
During the chronic phase, we observed a significant increase in T EM populations. This is most likely explained by a T CM population capable of continuous high-level production of new T EM (46) . Comparing the T cell population in the acute versus chronic phases of HIV infection, we observed a prominent contraction of CD4 + T N , whereas the T EM population expanded, in the chronic phase; the contraction/expansion of CD4 + T cell subsets that we observed was similar to that observed in HIV-infected NSG mice (30) . Notably, the distribution of splenic T cell subsets in uninfected MISTRG mice resembled that of reconstituted NSG mice (47) and of healthy humans (48) . During acute infection, T EMRA were positive for PD-1 expression, which is a regulator of T cell activation (49) and a marker of exhaustion during viral infections (50, 51) . The expression of PD-1 in hu mice was reminiscent of the findings in humans suffering from acute HIV infection (44, 52) . However, at the later stage of infection, an increase in PD-1 levels was also observed on CD4 + T CM and T EM , as well as on CD8 + T EM , resembling the findings in individuals in chronic stages of HIV infection
We detected activated CD4 + and CD8 + T cells by means of coexpression of HLA-DR and CD38 in MISTRG mice infected with YU-2. This represents one of the major hallmarks of HIV infection (53) (54) (55) . The frequencies of activated CD4 + and CD8 + T cells correlated with HIV RNA copy numbers, in line with findings in HIV-infected humans (54) . We found lower CD4 + T cell levels during NL4-3 infection, which is explained by the highly cytopathic effect of this virus strain (41, 56) . These findings were confirmed by analyzing the cell-activation pattern in the spleen of HIV-infected MISTRG mice, where we found substantially higher frequencies of activated CD8 + splenocytes. Therefore, these two novel humanized mouse models mirror some of the key aspects of acute and chronic HIV infection.
Strikingly, we observed a one-log difference in HIV viral load between MISTRG and MITRG mice, which was apparent at 4-8 wk p.i. and persisted throughout the acute phase. MISTRG mice differ from MITRG mice solely by the transgenic expression of the human don't-eat-me signal, SIRPa. We hypothesized that this signal prevents the clearance of human lymphoid cells, which primarily express CD47, and thereby, promotes the expansion of the pool of potential HIV target cells. It might also prevent the loss of HIV-infected cells. Indeed, MISTRG mice, unlike MITRG mice, showed a progressive increase in CD3 + T cell levels. Thus, we further hypothesized that we can revert this profile by depletion of murine macrophages in MITRG mice. We used CLDs to deplete the mononuclear phagocytic cells and found that CLDs selectively affected the mouse tissue-resident macrophages that develop during embryogenesis (57) . In concordance with previous studies (58, 59) , the depletion resulted in substantially higher engraftment levels and, indeed, in substantially higher viral loads. Thus, we obtained an HIV-replication profile in MITRG mice resembling MISTRG mice by preventing macrophage-mediated engulfment of human cells with CLDs. In addition to the overall enhanced engraftment levels, depletion of tissue-resident macrophages resulted in elevated levels of NKp46 + cells in the blood at early time points of infection that we did not observe previously in any other experiment. Human CD68 + CD163
+ and CD68 + CD163 2 macrophages, which most likely have a monocytic origin, were also increased in CLD-treated MITRG mice. We explain the elevated macrophage reconstitution by the overall elevated levels of myeloid cells. We also observed a tendency for increased frequencies of CD68 + CD163 + macrophages in CLD-treated and YU-2-infected animals. Similar observations were reported during SIV infection (60, 61) , and soluble CD163 has been suggested as a biomarker for attempts of the immune system to resolve immune activation induced by HIV (62) . Thus, data obtained using macrophage-depleted humanized MITRG mice are reminiscent of the data in MISTRG mice and point to a central role for SIRPa expression on macrophages in MISTRG mice for the phenotype observed. The exact role of SIRPa in HIV pathogenesis remains to be determined.
In addition, CLD treatment revealed the same elevation in viral load in MISTRG mice as in MITRG mice, without any increase in engraftment or target cells, excluding an effect related to the proportional amount of target cells. Our observation might be explained by the fact that MISTRG mice express human and murine SIRPa, and a residual phagocytic activity by murine macrophages cannot be excluded. Human macrophages appear to be infected by engulfed HIV-infected CD4 + T cells, which leads to substantially elevated HIV RNA levels in vitro (63) .
We also compared the HIV-replication rate of MISTRG/ MITRG mice with other humanized mouse models that we used over the years (26, 35, 64, 65) . Advantageously, we have been using the identical infection procedure and even the same R5-tropic HIV strain, YU-2. In fact, the extent of HIV replication was the same in MISTRG mice as in hu Rag2
, NOG, and NSG mice; all of these latter hu mice had a distinct overall engraftment level (20.5 6 22.3, 20.7 6 13.2, and 48.8 6 16.7% [average 6 SD], respectively, hCD45 + cells of all viable mononucleated cells) that points to factors other than the engraftment level determining the viralreplication rate. The MITRG mice set themselves apart with their one-log lower viral-replication rate, especially in comparison with MISTRG mice. After the initial viral peak, MISTRG mice exhibited a constant decrease in viral burden and changes in the memory/effector T cell compartments over time. To assess the contribution of CD8 + T cells, we depleted them before HIV infection. Unexpectedly, we did not see any increase in viral load in HIV-infected MISTRG mice, negating a potential CD8 + T cell-driven antiviral effect.
These data are in line with a previous study that also found that depletion of CD8 + T cells prior to HIV infection had no effect on lowering HIV (66) ; in that study, the investigators concluded that acute HIV replication in humanized NSG mice is primarily constrained by the number of available targets in lymphoid tissue rather than by CD8 + T cells. In our hands, however, there were substantially fewer CD4 + T cells in the spleen of depleted and infected animals than in depleted and HIV 2 MISTRG mice, and there was a tendency for increased CD4 + T cell levels in infected and undepleted MISTRG mice. This constellation is consistent with a role for CD8 + T cells in preventing CD4 + T cell loss early during HIV infection in CD34 + -reconstituted MISTRG mice. Alternatively, we have to consider that the latter finding is strictly due to a depletion of CD4 + CD8
+ double-positive thymocytes, with subsequent reduced CD4 + T cell reconstitution. In contrast to the above-discussed findings, HIV-specific CD8 + T cells are present in chronically HIV-infected NSG mice, and their depletion at this later time point resulted in an increase in viral load (67) . In addition, we did not detect any human HIV-specific IgG at 12 and 20 wk p.i., consistent with published data (68) . The lack of human HIV-specific IgG is largely explained by the predominance of immature B cells (24) . However, some improvement could be achieved by cotransplanting human fetal liver and thymic tissue (69) or the expression of IL-6 (70, 71) . These approaches would probably also result in elevated frequencies of HIV-specific T cells. Another limitation was the observation of anemia mainly in MISTRG mice related to high engraftment and leading to their exclusion from experiments, although we did not irradiate them. A solution might be to use fewer HSPCs for transplantation, with possible impairment in engraftment. Notably, we did not observe graft-versus-host disease, which is regularly seen in humanized NSG mice (72) , at any time point.
In summary, MITRG and MISTRG mice support HIV replication. Because of superior development of myeloid cells compared with existing humanized mouse models, this model offers the opportunity to study innate immune system modulators (73, 74) and PD-1 inhibitors (75, 76) as treatment for HIV infection. In addition, the roles of CD47 and SIRPa could be studied during infection in MISTRG mice, because the role of this interaction has not yet been defined for HIV, in contrast to cancer and different infectious diseases (77) (78) (79) . Furthermore, MISTRG mice mirror key features of HIV infection and offer a favorable model to study the various myeloid cell types involved in HIV infection.
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